A SUR2B/Kir6.1 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VU0542270

Item No. 43074

Technical Information
Formal Name
N-[[4-methyl-2-(2-thienyl)-5-thiazolyl]methyl]-N′-2-thienyl-urea
CAS Number
1396814-79-1
Molecular Formula
C14H13N3OS3
Formula Weight
Purity
≥98%
Formulation
A solid
DMSO: Sparingly soluble: 1-10 mg/mlEthanol: Slightly soluble: 0.1-1 mg/ml
SMILES
O=C(NCC1=C(C)N=C(C2=CC=CS2)S1)NC3=CC=CS3
InChi Code
InChI=1S/C14H13N3OS3/c1-9-11(21-13(16-9)10-4-2-6-19-10)8-15-14(18)17-12-5-3-7-20-12/h2-7H,8H2,1H3,(H2,15,17,18)
InChi Key
HMFDAWDOVRPGGW-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    VU0542270 is an inhibitor of sulfonylurea receptor 2B (SUR2B) linked to ATP-sensitive potassium channel Kir6.1 (SUR2B/Kir6.1; IC50 = 0.11 µM).1 It is selective for SUR2B/Kir6.1 over ten other inward-rectifier potassium channels (Kirs; IC50s = >30 µM for all). VU0542270 (10 or 100 µM) induces constriction in isolated mouse ductus arteriosus vessels.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Li, K., McClenahan, S.J., Han, C., et alDiscovery and characterization of VU0542270, the first selective inhibitor of vascular Kir6.1/SUR2B KATP channels. Mol. Pharmacol. 105(3), 202-212 (2024).